Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra P...
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
...
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-07-19
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 4
- Registration Number
- NCT00006747
- Locations
- 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸University of Massachusetts Memorial Medical Center - University Campus, Worcester, Massachusetts, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia
- First Posted Date
- 2002-06-04
- Last Posted Date
- 2015-09-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT00038610
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-11-01
- Target Recruit Count
- 33
- Registration Number
- NCT00000801
- Locations
- 🇺🇸
Julio Arroyo, West Columbia, South Carolina, United States
🇺🇸San Francisco Gen Hosp, San Francisco, California, United States
🇺🇸San Francisco AIDS Clinic / San Francisco Gen Hosp, San Francisco, California, United States
A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 250
- Registration Number
- NCT00000658
- Locations
- 🇺🇸
UCLA CARE Center CRS, Los Angeles, California, United States
🇺🇸USC CRS, Los Angeles, California, United States
🇺🇸Ucsf Aids Crs, San Francisco, California, United States
Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 90
- Registration Number
- NCT00001048
- Locations
- 🇺🇸
Northwestern University CRS, Chicago, Illinois, United States
🇺🇸University of Colorado Hospital CRS, Aurora, Colorado, United States
🇺🇸Univ. of Miami AIDS CRS, Miami, Florida, United States
Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 45
- Registration Number
- NCT00000703
- Locations
- 🇺🇸
Univ of Massachusetts Med Ctr, Worcester, Massachusetts, United States
🇺🇸Julio Arroyo, West Columbia, South Carolina, United States
🇺🇸Milton S Hershey Med Ctr, Hershey, Pennsylvania, United States
Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-02
- Target Recruit Count
- 18
- Registration Number
- NCT00000689
- Locations
- 🇺🇸
USC CRS, Los Angeles, California, United States
Phase II Pilot Study of Cytarabine for Refractory Systemic Lupus Erythematosus
- Conditions
- First Posted Date
- 2000-02-25
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 10
- Registration Number
- NCT00004643
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.